Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−27.47 USD
−7.79 M USD
0.00 USD
1.48 M
About Dermata Therapeutics, Inc.
Sector
CEO
Gerald T. Proehl
Headquarters
San Diego
Website
Founded
2014
FIGI
BBG011DJT0X2
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of DRMA is 1.39 USD — it has decreased by −0.74% in the past 24 hours. Watch Dermata Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Dermata Therapeutics, Inc. stocks are traded under the ticker DRMA.
DRMA stock has risen by 2.29% compared to the previous week, the month change is a 0.75% rise, over the last year Dermata Therapeutics, Inc. has showed a −87.77% decrease.
We've gathered analysts' opinions on Dermata Therapeutics, Inc. future price: according to them, DRMA price has a max estimate of 6.00 USD and a min estimate of 6.00 USD. Watch DRMA chart and read a more detailed Dermata Therapeutics, Inc. stock forecast: see what analysts think of Dermata Therapeutics, Inc. and suggest that you do with its stocks.
DRMA reached its all-time high on Nov 3, 2021 with the price of 1,668.00 USD, and its all-time low was 1.22 USD and was reached on Oct 14, 2024. View more price dynamics on DRMA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
DRMA stock is 16.66% volatile and has beta coefficient of −0.71. Track Dermata Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Dermata Therapeutics, Inc. there?
Today Dermata Therapeutics, Inc. has the market capitalization of 2.02 M, it has decreased by −2.17% over the last week.
Yes, you can track Dermata Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Dermata Therapeutics, Inc. is going to release the next earnings report on Nov 8, 2024. Keep track of upcoming events with our Earnings Calendar.
DRMA earnings for the last quarter are −4.18 USD per share, whereas the estimation was −3.79 USD resulting in a −10.29% surprise. The estimated earnings for the next quarter are −2.64 USD per share. See more details about Dermata Therapeutics, Inc. earnings.
DRMA net income for the last quarter is −2.83 M USD, while the quarter before that showed −3.13 M USD of net income which accounts for 9.74% change. Track more Dermata Therapeutics, Inc. financial stats to get the full picture.
No, DRMA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 8.00 employees. See our rating of the largest employees — is Dermata Therapeutics, Inc. on this list?
Like other stocks, DRMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Dermata Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Dermata Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Dermata Therapeutics, Inc. stock shows the sell signal. See more of Dermata Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.